TScan Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from TScan Therapeutics Inc
Access all reports
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell (TCR-T) therapies to treat cancer. The company's lead candidates, TSC-100 and TSC-101, target hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. Additionally, TScan is advancing a pipeline of multiplexed TCR-T therapies for solid tumors, supported by its proprietary ImmunoBank, which houses a diverse collection of therapeutic TCRs. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
TCRX
Country
🇺🇸 United States